(0.32%) 5 116.17 points
(0.38%) 38 386 points
(0.35%) 15 983 points
(-0.12%) $82.53
(0.94%) $2.05
(-0.49%) $2 346.20
(-1.07%) $27.37
(-0.33%) $958.30
(-0.18%) $0.933
(-0.28%) $10.99
(-0.53%) $0.796
(1.56%) $93.31
0.30% $ 26.63
@ $38.32
Ausgestellt: 14 Feb 2024 @ 21:08
Rendite: -30.51%
Vorheriges Signal: Feb 13 - 21:48
Vorheriges Signal:
Rendite: -0.52 %
Live Chart Being Loaded With Signals
Arcturus Therapeutics Holdings Inc., an RNA medicines company, focuses on the development of vaccines for infectious, and liver and respiratory rare diseases in the United States...
Stats | |
---|---|
Tagesvolumen | 280 676 |
Durchschnittsvolumen | 486 820 |
Marktkapitalisierung | 716.75M |
EPS | $0 ( 2024-03-07 ) |
Nächstes Ertragsdatum | ( $-1.190 ) 2024-06-13 |
Last Dividend | $0.0596 ( 2013-01-08 ) |
Next Dividend | $0 ( N/A ) |
P/E | -23.78 |
ATR14 | $0.0490 (0.18%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-03-25 | Chivukula Pad | Sell | 17 435 | Common Stock |
2024-03-19 | Chivukula Pad | Sell | 8 565 | Common Stock |
2023-12-15 | Sassine Andy | Buy | 75 000 | Employee Stock Option (right to buy) |
2023-12-15 | Chivukula Pad | Buy | 125 000 | Employee Stock Option (right to buy) |
2023-12-15 | Kurata Lance | Buy | 75 000 | Employee Stock Option (right to buy) |
INSIDER POWER |
---|
78.05 |
Last 97 transactions |
Buy: 2 555 134 | Sell: 1 046 972 |
Volumen Korrelation
Arcturus Therapeutics Korrelation
10 Am meisten positiv korreliert | |
---|---|
AVEO | 0.955 |
ITMR | 0.949 |
RBNC | 0.939 |
HEAR | 0.932 |
SUMR | 0.929 |
FCBP | 0.92 |
DVCR | 0.92 |
RMRM | 0.918 |
AMYT | 0.917 |
EA | 0.917 |
10 Am meisten negativ korreliert | |
---|---|
SBNY | -0.929 |
IMV | -0.925 |
DPRO | -0.92 |
NDRA | -0.913 |
MNDO | -0.91 |
CLDX | -0.909 |
SSPK | -0.909 |
WABC | -0.908 |
DFFN | -0.907 |
TCBC | -0.907 |
Wussten Sie das?
Korrelation ist ein statistisches Maß, das die Beziehung zwischen zwei Variablen beschreibt. Es reicht von -1 bis 1, wobei -1 eine perfekte negative Korrelation (wenn eine Variable zunimmt, nimmt die andere ab) anzeigt, 1 eine perfekte positive Korrelation (wenn eine Variable zunimmt, nimmt die andere zu) und 0 keine Korrelation anzeigt (es besteht kein Zusammenhang zwischen den Variablen).
Korrelation kann verwendet werden, um die Beziehung zwischen beliebigen zwei Variablen zu analysieren, nicht nur zwischen Aktien. Es wird häufig in Bereichen wie Finanzen, Wirtschaft, Psychologie und mehr verwendet.
Arcturus Therapeutics Korrelation - Währung/Rohstoff
Arcturus Therapeutics Finanzdaten
Annual | 2023 |
Umsatz: | $157.75M |
Bruttogewinn: | $154.79M (98.13 %) |
EPS: | $-1.120 |
FY | 2023 |
Umsatz: | $157.75M |
Bruttogewinn: | $154.79M (98.13 %) |
EPS: | $-1.120 |
FY | 2022 |
Umsatz: | $205.76M |
Bruttogewinn: | $62.70M (30.48 %) |
EPS: | $0.350 |
FY | 2021 |
Umsatz: | $12.36M |
Bruttogewinn: | $0.00 (0.00 %) |
EPS: | $-7.74 |
Financial Reports:
No articles found.
Arcturus Therapeutics Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
First Dividend | $0.0200 | 2012-03-06 |
Last Dividend | $0.0596 | 2013-01-08 |
Next Dividend | $0 | N/A |
Payout Date | 2013-01-15 | |
Next Payout Date | N/A | |
# dividends | 12 | -- |
Total Paid Out | $0.679 | -- |
Avg. Dividend % Per Year | 0.00% | -- |
Score | 2.12 | -- |
Div. Sustainability Score | 1.571 | |
Div.Growth Potential Score | 0 | |
Div. Directional Score | 0 | -- |
Year | Amount | Yield |
---|---|---|
2012 | $0 | 0.00% |
2013 | $0.119 | 0.23% |
2014 | $0 | 0.00% |
2015 | $0 | 0.00% |
2016 | $0 | 0.00% |
2017 | $0 | 0.00% |
2018 | $0 | 0.00% |
2019 | $0 | 0.00% |
2020 | $0 | 0.00% |
2021 | $0 | 0.00% |
2022 | $0 | 0.00% |
2023 | $0 | 0.00% |
2024 | $0 | 0.00% |
The company's low Dividend Sustainability Score (DSS) highlights potential challenges in upholding its current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. In conclusion, a more vigilant stance is recommended given the company's tentative dividend landscape.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
OXSQ | Dividend Diamond | 2023-12-14 | Monthly | 21 | 9.10% | 8.50 |
PSEC | Dividend Royal | 2023-12-26 | Monthly | 21 | 7.04% | 8.50 |
SLVO | Dividend Royal | 2023-11-20 | Monthly | 12 | 10.77% | 8.50 |
QYLD | Dividend Royal | 2023-11-20 | Monthly | 11 | 7.50% | 8.50 |
GAIN | Dividend Royal | 2023-12-04 | Monthly | 20 | 8.19% | 8.50 |
GLDI | Dividend Royal | 2023-11-20 | Monthly | 12 | 7.15% | 8.50 |
OXLC | Dividend Royal | 2023-12-14 | Monthly | 14 | 10.00% | 8.50 |
HRZN | Dividend King | 2023-12-18 | Monthly | 15 | 6.60% | 8.45 |
USOI | Dividend Royal | 2023-11-20 | Monthly | 8 | 16.70% | 8.28 |
PFLT | Dividend King | 2023-11-15 | Monthly | 14 | 6.50% | 8.27 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | -0.165 | 1.500 | -3.31 | -4.96 | [0 - 0.5] |
returnOnAssetsTTM | -0.0619 | 1.200 | -2.06 | -2.48 | [0 - 0.3] |
returnOnEquityTTM | -0.0907 | 1.500 | -2.12 | -3.18 | [0.1 - 1] |
payoutRatioTTM | 0 | -1.000 | 0 | 0 | [0 - 1] |
currentRatioTTM | 4.72 | 0.800 | 10.00 | 8.00 | [1 - 3] |
quickRatioTTM | 4.62 | 0.800 | 10.00 | 8.00 | [0.8 - 2.5] |
cashRatioTTM | 4.23 | 1.500 | 10.00 | 10.00 | [0.2 - 2] |
debtRatioTTM | 0.0704 | -1.500 | 8.83 | -10.00 | [0 - 0.6] |
interestCoverageTTM | -92.63 | 1.000 | -10.00 | -10.00 | [3 - 30] |
operatingCashFlowPerShareTTM | -0.677 | 2.00 | -0.226 | -0.451 | [0 - 30] |
freeCashFlowPerShareTTM | -0.784 | 2.00 | -0.392 | -0.784 | [0 - 20] |
debtEquityRatioTTM | 0.108 | -1.500 | 9.57 | -10.00 | [0 - 2.5] |
grossProfitMarginTTM | 0.341 | 1.000 | 7.65 | 7.65 | [0.2 - 0.8] |
operatingProfitMarginTTM | -0.442 | 1.000 | -10.00 | -10.00 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | -0.596 | 1.000 | -4.42 | -4.42 | [0.2 - 2] |
assetTurnoverTTM | 0.375 | 0.800 | -0.836 | -0.668 | [0.5 - 2] |
Total Score | 1.571 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | -26.59 | 1.000 | -2.79 | 0 | [1 - 100] |
returnOnEquityTTM | -0.0907 | 2.50 | -1.362 | -3.18 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | -0.784 | 2.00 | -0.261 | -0.784 | [0 - 30] |
dividendYielPercentageTTM | 0 | 1.500 | 0 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | -0.677 | 2.00 | -0.226 | -0.451 | [0 - 30] |
payoutRatioTTM | 0 | 1.500 | 0 | 0 | [0 - 1] |
pegRatioTTM | -0.444 | 1.500 | -6.29 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | -0.112 | 1.000 | -5.30 | 0 | [0.1 - 0.5] |
Total Score | -2.19 |
Arcturus Therapeutics
Arcturus Therapeutics Holdings Inc., an RNA medicines company, focuses on the development of vaccines for infectious, and liver and respiratory rare diseases in the United States. The company's development programs comprise LUNAR-OTC development program for ornithine transcarbamylase (OTC) deficiency; and LUNAR-CF program for cystic fibrosis lung disease caused by mutations in cystic fibrosis transmembrane conductance regulator (CFTR) gene, as well as vaccine programs include LUNAR-COV19 and LUNAR-FLU. It has collaboration partnerships with Vinbiocare Biotechnology Joint Stock Company for the manufacture of COVID-19 vaccines; Janssen Pharmaceuticals, Inc. to develop nucleic acid-based therapeutic candidates for the treatment of hepatitis B virus; Ultragenyx Pharmaceutical, Inc. to develop mRNA therapeutic candidates for rare disease targets; CureVac AG to develop mRNA therapeutic and vaccine candidates for various indications; Singapore Economic Development Board and Duke-NUS Medical School to develop LUNAR-COV19 vaccine; and Millennium Pharmaceuticals, Inc. to discover siRNA medicines for the treatment of non-alcoholic steatohepatitis. The company was founded in 2013 and is headquartered in San Diego, California.
Über Live-Signale
Die Live-Signale auf dieser Seite helfen dabei zu bestimmen, wann man NA kaufen oder verkaufen soll. Die Signale haben eine Verzögerung von bis zu 1 Minute; wie bei allen Marktsignalen besteht die Möglichkeit von Fehlern oder Fehleinschätzungen.
Die Live-Handelssignale sind nicht endgültig und getagraph.com übernimmt keine Verantwortung für Maßnahmen, die aufgrund dieser Signale ergriffen werden, wie in den Nutzungsbedingungen beschrieben. Die Signale basieren auf einer breiten Palette von technischen Analyseindikatoren.